Factor VIII and transmissible spongiform encephalopathy: The case for safety

Haemophilia

Volumn 8, Issue 2, 2002, Pages 63-75

  Cervenakova, Larisa ^a   Brown, P ^a   Hammond, D J ^a   Lee, C A ^a   Saenko, E L ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

Blood; Factor VIII; Prion disease; Safety; Transmissible spongiform encephalopathy; Variant Creutzfeldt Jakob disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; MONARC M; PRION PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL; BLOODBORNE BACTERIUM; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; DRUG CONTAMINATION; HEMOPHILIA A; HUMAN; INFECTION CONTROL; MALE; METHODOLOGY; PRION DISEASE; REVIEW; BIOASSAY; BLEEDING DISORDER; BLOOD COMPONENT THERAPY; BRAIN SPONGIOSIS; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG SAFETY; HYPOTHESIS; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; INFECTION; ION EXCHANGE CHROMATOGRAPHY; MICROBIAL CONTAMINATION; MOUSE; NONHUMAN; PRION; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE CULTURE; WESTERN BLOTTING;

ANIMALS; BLOOD-BORNE PATHOGENS; CREUTZFELDT-JAKOB SYNDROME; DRUG CONTAMINATION; FACTOR VIII; HEMOPHILIA A; HUMANS; INFECTION CONTROL; MALE; PRION DISEASES;

EID: 0036489588     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00617.x     Document Type: Review

References (110)

1. Kemball-Cook G, Tuddenham EGD. The factor VIII mutation database on the world wide web: the Haemophilia A Mutation, Search, Test and Resource site. HAMSTeRS Update (Version 3.0). Nucleic Acids Res 1997; 25: 128-32.
2. Giannelli F, Green PM, Sommer SS et al. Database of point mutations and short additions and deletions, 7th edn. Nucleic Acids Res 1997; 25: 133-5.
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
4. Saenko EL, Shima M, Sarafanov AG. Role of activation of the coagulation factor VIII in interaction with vWF, phospholipid, and functioning within the factor Xase complex. Trends Cardiovasc Med 1999; 9 (7): 185-92.
5. Fay PJ. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost 1999; 82 (2): 193-200.
6. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272 (29): 18007-14.
7. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82 (2): 165-74.
8. Furie B, Limentani SA, Rosenfield CG. Practical guide to the evaluation and treatment of haemophilia. Blood 1994; 84 (1): 3-9.
9. Rizza CR, Spooner RJ, Giangrande PL, The UK Haemophilia Centre Doctors' Organization (UKC-DO). Treatment of haemophilia in the United Kingdom 1981-96. Haemophilia 2001; 7 (4): 349-59.
10. Fijnvandraat K, Berntorp E, ten Cate JW et al. Recombinant B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in haemophilia A patients. Thromb Haemost 1997; 77 (2): 298-302.
11. Mannucci PM, Tuddenham EG. The haemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344 (23): 1773-9.
12. Ludlam CA. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet 1997; 350: 1704.
13. Ludlam CA. New-variant Creutzfeldt-Jakob disease, treatment of haemophilia. Executive Committee of the UK Haemophilia Director's Organisation. Lancet 1998; 351: 1289-90.
14. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of haemophilia A in home therapy. International Kogenate-FS Study Group. Thromb Haemost 2000; 83 (6): 811-6.
15. Ludlam CA. Viral safety of plasma-derived factor VIII and IX concentrates. Blood Coagul Fibrinol 1997; 8 (Suppl. 1): S19-S23.
16. Sugawara H, Motokawa R, Abe H et al. Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU-E derived from peripheral blood. Transfusion 2001; 41: 456-61.
17. Brown P. Transmissible human spongiform encephalopathy (Infectious cerebral amyloidosis): Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome and kuru. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia: WB Saunders, 1994: 839-76.
18. Sparkes RS, Simon M, Cohn VH et al. Assignment of the human and mouse prion protein genes to homologous chromosomes. Proc Natl Acad Sci USA 1986; 83: 7358-62.
19. Gajdusek DC. Infectious amyloids: subacute spongiform encephalopathies as transmissible cerebral amyloidosis. In: Knipe BN, Howley PM, eds. Field's Virology, 3rd edn. Philadelphia: Lippincott-Raven Publishers, 1996: 2862-70.
20. Prusiner SB, Gajdusek DC, Alpers MP. Kuru with incubation periods exceeding two decades. Ann Neurol 1982; 12: 1-9.
21. Verity CM, Nicoll A, Will RG, Devereux G, Stellitano L. Variant Creutzfeldt-Jakob disease in UK children: a national surveillance study. Lancet 2000; 356: 1224-7.
22. Brown P, Preece M, Will R. 'Friendly fire' in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992; 340: 24-7.
23. Brown P. Transmission of spongiform encephalopathy through biological products. Dev Biol Stand Basel: Karger. 1998; 93: 73-8.
24. Will RG, Ironside JM, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.
25. Department of Health. Monthly statistics URL: www.doh.gov.uk/cjd/stats/nov0l.htm.
26. Dorozynski A. France prepares for more cases of vCJD. BMJ 2000; 321 (7271): 1241.
27. Dervaux A, Vicart S, Lopes F, Le Borgne MH. Psychiatric features of vCJD similar in France and UK. Br J Psych 2001; 178: 276.
28. Bichard K. Variant Creutzfeldt-Jakob disease found in Ireland. Lancet 1999; 353: 2221.
29. Ironside J. Prion inactivation - Risk for variant CJD. PPTA Workshop: 'The policies and science of prions and plasma', Washington DC, USA, October 23-24, 2001.
30. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-90.
31. Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
32. Hill AF, Desbruslais M, Joiner S et al. The same prion strain causes nvCJD and BSE. Nature 1997; 389: 448-50.
33. Scott MR, Will RG, Ironside JW et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA 1999; 96 (26): 15137-42.
34. Prusiner S. Prions. Proc Natl Acad Sci USA 1998; 95: 13363-83.
35. Pan K-M, Baldwin M, Nguyen J et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993; 90: 10962-6.
36. Telling GC, Scott M, Mastrianni J et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995; 83: 79-90.
37. Brown DR. Copper and prion disease. Brain Res Bull 2001; 55: 165-73.
38. Cashman NR, Loertscher R, Nalbantoglu J et al. Cellular isoform of the scrapie agent protein participates in lymphocytes activation. Cell 1990; 61: 185-92.
39. Bendheim PE, Brown HR, Rudelli RD et al. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 1992; 42: 149-56.
40. Meiner Z, Halimi M, Polakiewicz RD, Prusiner SB, Gabizon R. Presence of prion protein in peripheral tissues of Libyan Jews with Creutzfeldt-Jakob disease. Neurology 1992; 42: 1355-60.
41. 27-30 is a normal soluble prion protein fragment released by human platelets. Biochem Biophys Res Commun 1996; 223: 572-7.
42. Perini F, Frangione B, Prelli F. Prion protein released by platelets. Lancet 1996; 347: 1635-6.
43. Dodelet VC, Cashman NR. Prion protein expression in human leukocyte differentiation. Blood 1998; 91: 1556-61.
44. Holada K, Mondoro TH, Muller J, Vostal JG. Increased expression of phosphatidylinositol-specific phospholipase C resistant prion proteins on the surface of activated platelets. Br J Hematol 1998; 103: 276-82.
45. Barclay R, Hope J, Birkett CR, Turner ML. Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry. Br J Haematol 1999; 107: 804-14.
46. Vostal JG, Holada K, Simak J. Expression of cellular prion protein on blood cells: Potential functions in cell physiology and pathophysiology of transmissible spongiform encephalopathy diseases. Transfus Med Rev 2001; 15: 268-81.
47. MacGregor I. Prion protein and developments in its detection. Transfus Med 2001; 11: 3-14.
48. Dealler S. A matter for debate: the risk of bovine spongiform encephalopathy to humans posed by blood transfusion in the UK. Transfus Med 1996; 6: 217-22.
49. Hill AF, Zeidler M, Ironside JW, Collinge J. Diagnosis of new variant Creutzfedt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100.
50. Hill AF, Butterworth RJ, Joiner S et al. Investigation of variant Creutzfedt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1997; 353: 183-9.
51. Kawashima I, Furukawa H, Doh-ura K, Iwaki T. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 350: 68-9.
52. Wadsworth JDF, Joiner S, Hill AF et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358: 171-80.
53. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703-4.
54. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001; 358: 208-9.
55. Houston DM, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
56. Hadlow WJ, Kennedy RC, Race RE, Eklund CM. Virologic and neurohistologic findings in dairy goats affected with natural scrapie. Vet Pathol 1980; 17: 187-99.
57. Hadlow WJ, Kennedy RC, Race RE. Natural infection of Suffolk sheep with scrapie virus. J Infect Dis 1982; 146: 657-64.
58. Pattison J. The emergence of bovine spongiform encephalopathy and related diseases. Emerg Infect Dis 1998; 4: 390-4.
59. Gibbs CJ Jr, Gajdusek DC, Morris JA. Viral characteristics of the scrapie agent in mice. In: Gajdusek DC, Gibbs CJ Jr, Alpers M, eds. Slow, Latent, and Temperate Virus Infections. NINDB monograph no. 2, PHS Publication no. 1378. Washington DC: US Government Printing Office, 1965: 195-202.
60. Clarke MC, Haig DA. Presence of the transmissible agent of scrapie in the serum of affected mice and rats. Vet Rec 1967; 80: 504.
61. Dickinson AG, Mickle VMH. Genetic control of the concentration of ME7 scrapie agent in the brain of mice. J Comp Pathol 1969; 79: 15-22.
62. Diringer H. Sustained viremia in experimental hamster scrapie. Arch Virol 1984; 82: 105-9.
63. Casaccia P, Ladogana A, Xi YG, Pocchiari M. Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Arch Virol 1989; 108: 145-9.
64. Manuelidis EE, Gorgacz EJ, Manuelidis L. Viremia in experimental Creutzfeldt-Jakob disease. Science 1978; 200: 1069-71.
65. Kuroda Y, Gibbs CJ Jr, Amyz HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983; 41: 154-61.
66. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-6.
67. Brown P, Cervenakova L, McShane LM, Barber P, Drohan WN. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood products do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
68. Drohan WN, Cervenakova L. Safety of blood products: Are transmissible spongiform encephalopathies (prion diseases) a risk? Thromb Haemost 1999; 82: 486-93.
69. Taylor DM, Fernie K, Reichel HE, Somerville RA. Infectivity in the blood of mice with a BSE-derived agent. J Hospital Infect 2000; 46: 78-9.
70. Rohwer RG. Titer, distribution, and transmissibility of blood-borne TSE infectivity. Cambridge Healthtech Institute 6th Annual Meeting 'Blood Product Safety: TSE, Perception versus Reality', MacLean, Virginia February 13-15, 2000.
71. Tateishi J. Transmission of Creutzfeldt-Jakob disease from human blood and urine into mice. Lancet 1985; ii: 1074.
72. Deslys JP, Lasmezas C, Dormont D. Selection of specific strains in iatrogenic Creutzfeldt-Jakob disease. Lancet 1994; 343: 848-9.
73. Manuelidis EE, Kim JH, Mericangas JR, Manuelidis L. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet 1985; ii: 896-7.
74. Tamai Y, Kojuma H, Kitajima R et al. Demonstration of the transmissible agent in tissue from a pregnant woman with Creutzfeldt-Jakob disease. 1992; 327: 649.
75. Brown P, Gibbs CJ, Rodgers-Johnson P et al. Human spongiform encephalopathy. The National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35: 513-29.
76. Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med 2001; 137: 5-15.
77. Davanipour Z, Alter M, Sobel E, Asher DM, Gajdusek DC. Creutzfeldt-Jakob disease: possible medical risk factors. Neurology 1985; 35: 1483-6.
78. Wilson K, Code C, Ricketts M. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies. BMJ 2000; 321: 17-9.
79. Kondo K, Kuroiwa Y. A case control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann Neurol 1982; 11: 377-81.
80. Harries-Jones R, Knight R, Will RG, Cousens S, Smith PG, Matthews WB. Creutzfeldt-Jakob disease in England and Wales. 1980-84: a case control study of potential risk factors. J Neurol Neurosurg Psychiatry 1988; 51: 1113-9.
81. Esmonde TFG, Will RG, Slattery JM et al. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993; 341: 205-7.
82. Wientjens DPWM, Davanipour Z, Hofman A et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996; 46: 1287-91.
83. Van Duijn CM, Delasnerie-Laupetre N, Masullo C et al. Case-Control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. Lancet 1998; 351: 1081-5.
84. Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL. Surgical treatment and risk of sporadic Creutzfedt-Jakob disease: a case-control study. Lancet 1999; 353: 693-7.
85. Evatt B, Austin H, Barnhart E et al. Surveillance for Creutzfeldt-Jakob disease among persons with haemophilia. Transfus 1998; 38: 817-20.
86. Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States 1979-94: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996; 2: 333-7.
87. Lee CA, Ironside JW, Bell JE et al. Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost 1998; 80: 909-11.
88. Sullivan MT, Schonberger LB, Kessler D, Williams AE, Dodd RY. Creutzfeldt-Jakob disease (CJD) investigational look back study. Transfusion 1997; 37 (Suppl.): 2S.
89. Heye N, Hensen S, Möller N. Creutzfeldt-Jakob Disease and blood transfusion. Lancet 1994; 343: 298-9.
90. Volkel D, Zimmermann K, Zerr I et al. Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases. Transfusion 2001; 41: 441-8.
91. Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. JBC 2001; 276: 31479-82.
92. Miele G, Manson J, Clinton M. A novel erythroidspecific marker of transmissible spongiform encephalopathies. Nature Med 2001; 7: 361-4.
93. MacGregor L Prion protein and developments in its detection. Transfus Med 2001; 11: 3-14.
94. Lee DC, Stenland C, Hartwell R et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Meth 2000; 84: 77-89.
95. Safar J, Wille H, Itri V et al. Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998; 4: 1157-65.
96. MacGregor I, Hope J, Barnard G et al. Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sang 1999; 77: 88-96.
97. SC by multi-spectral ultraviolet fluorescence. Biochem Biophys Res Comm 1998; 246: 100-6.
98. Schmerr MJ, Jenny A. A diagnostic test for scrapie-infected sheep using a capillary electrophoresis immunoassay with fluorescent-labeled peptides. Electrophoresis 1998; 19: 409-14.
99. Schmerr MJ, Jenny AL, Bulgin MS et al. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatog A 1999; 853: 207-14.
100. Bieschke J, Giese A, Schulz-Schaeffer W et al. Ultra-sensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluoresecent targets. Proc Natl Acad Sci USA 2000; 97: 5468-73.
101. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001; 411: 810-3.
102. Fischer MB, Roecki C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature 2000; 408: 479-83.
103. Maissen M, Roeckl C, Glatzel M, Goldmann W, Aguzzi A. Plasminogen binds to disease-associated prion protein of multiple species. Lancet 2001, June 23; 357 (9273): 2026-8.
104. Cashman N, Dodelet V, Paramithiotis E et al. A cell surface receptor for the prion protein. Soc Neurosci Abstract 1999; 25: 1567.
105. Lee DC, Stenland C, Miller JLC et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001. 41: 449-55.
106. Kasper CK, Costa e Silva M. Registry of Clotting Factor Concentrates, 3rd edn, 2001. Facts and Figures Monograph series, no. 6. Montreal: WFH.
107. Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999; 9: 3-14.
108. Foster PR, Welch AG, McLean C et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78: 86-95.
109. Baron H. Plasma prions and production of therapies. PPTA Workshop: 'The policies and science of prions and plasma', Washington DC, USA, October 23-24, 2001.
110. Drohan WN. Transmissible spongiform encephalopathies: needs perceived by the blood fractionation industry. International Workshop on Clearance of TSE Agents from Blood Products and Implanted Tissues, Gaithersburg MD, USA, September 13-14, 1999.